ACE-031Also known as: ACE-031 peptide, ActRIIB-Fc, Myostatin inhibitor protein, Recombinant fusion protein ACE-031

Mechanism of Action

ACE-031 is a recombinant fusion protein that acts as a decoy receptor for myostatin, a negative regulator of muscle growth. By binding circulating myostatin, ACE-031 prevents it from interacting with its natural receptor ActRIIB, effectively inhibiting myostatin signaling pathways that suppress muscle mass development. This blockade promotes increased muscle growth, hypertrophy, and may also positively impact bone density.

Reported Research Benefits

Laboratory research into muscle hypertrophy, muscle regeneration, prevention and treatment of muscle-wasting disorders (including Duchenne muscular dystrophy and sarcopenia), enhancement of muscle mass and strength, study of metabolic and body composition effects related to fat-free mass, and evaluation of therapeutic potential for conditions involving muscle atrophy.

Dosing Protocol & Reconstitution

Typically reconstituted from lyophilized powder with bacteriostatic water. Experimental administration in preclinical models is usually via subcutaneous injection. Exact dosing varies by study but often involves low microgram to milligram ranges adjusted per animal model weight or experimental design. Researchers are advised to use peptide calculators to determine precise dosing.

Research Notes

Preclinical studies demonstrate that ACE-031 rapidly increases muscle mass and prevents muscle loss due to aging or inactivity. It shows beneficial effects on muscle repair, regeneration, and also may increase bone mineral density. Half-life in vivo is extended relative to natural myostatin antagonists due to Fc fusion. The peptide's purity exceeds 99%, verified by independent testing.

Research Summary

ACE-031 (sotatercept precursor) is a fusion protein that acts as a decoy receptor for myostatin and related TGF-β ligands, blocking their inhibitory effects on muscle growth. Phase II trials in Duchenne muscular dystrophy patients showed meaningful increases in lean body mass. It also reduces bone resorption markers, suggesting dual muscle-bone protective effects.

Side Effects & Safety

Clinical trials reported epistaxis (nosebleeds), gingival bleeding, telangiectasias, and menstrual irregularities. Potential for elevated hemoglobin and erythropoiesis. Development discontinued for muscular dystrophy indications due to vascular side effects.

Stability & Storage

Refer to research notes

Molecular Data

Molecular Weight: 100000 g/mol
CAS Number: N/A

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=ACE-031+activin+receptor+myostatin